


2021 NCORP Annual Meeting Feedback Survey Screenshots

Overview

This document contains screenshots of each page within the 2021 NCORP Annual Meeting Feedback Survey. The page header containing the survey title is repeated on each page. To save space in this document, the header is omitted from Figures 2 – 46. The OMB number and expiration date are displayed at the top of the survey launch page (Figure 1), before the respondent accesses the first question in the survey.

Page Screenshots




OMB No.: 0925-0642
Expiration Date: 03/31/2023

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return the completed form to this address.

2021 NCORP Annual Meeting Feedback

[Click here to launch the 2021 NCORP Annual Meeting Feedback](#)

Figure 1. Survey launch page, with OMB information.



Have you attended an NCORP Annual Meeting before?

☐ No ☐ Yes

☐ Prefer not to Answer

Next Question

Figure 2. Overview – Question 1

What type of NCORP grantee do you represent?

- ☐ Research Base
- ☐ Community Site
- ☐ Minority/Underserved Site
- ☐ Other

☐ Prefer not to Answer

Previous Question

Next Question

Figure 3. Overview – Question 2

Please specify the type of NCORP grantee you represent.

☐ Prefer not to Answer

Previous Question

Next Question

Figure 4. Overview – Question 2 - Specify

What is your primary role in NCORP?

- ☐ NCORP Grantee Principal Investigator
- ☐ Physician Investigator
- ☐ Non-Physician Investigator
- ☐ NCORP Grantee Administrator
- ☐ CCDR Lead/Staff
- ☐ Research Base Staff (e.g., employee of NCORP Research Base)
- ☐ Community-Based Research Staff (e.g., employee of NCORP Community or MU Community NCORP site or affiliate)
- ☐ Patient Advocate
- ☐ NCI Staff
- ☐ Other

☐ Prefer not to Answer

Previous Question

Next Question

Figure 5. Overview – Question 3

Please specify your primary role in NCORP.

☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 6. Overview – Question 3 - Specify

Did you attend the Administrator Session?

☐ No ☐ Yes

☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 7. Administrator Session – Question 1

Administrator Session

For the next set of questions, please select the response which best represents the extent to which you agree or disagree for the Administrator sessions you attended.

[Previous Question](#)

[Next Question](#)

Figure 8. Administrator Session – Lead-in information

The **NCORP Director Overview** session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 9. Administrator Session – Question 2

The **NIH Grants: Policy Announcements and FAQs** session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 10. Administrator Session – Question 3

The **Federal Wide Assurances: What Investigators Should Know** session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 11. Administrator Session – Question 4

The **Quality Assurance: Getting Data Submitted on Time/Remote Auditing** session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 12. Administrator Session – Question 5

The **Tips and Tricks of EMR: How to Make it Work for You** session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 13. Administrator Session – Question 6

The **Rurality and NCORP Grants** session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 14. Administrator Session – Question 7

How would you rate the length of the Administrator Session?

- ☐ Too Long
- ☐ Just Right
- ☐ Too Short

- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 15. Administrator Session – Question 8

Administrator Session

Did you attend a Breakout Session?

- ☐ No ☐ Yes
- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 16. Administrator Session – Question 9

Please select which Breakout Session you attended.

- ☐ Staffing Essentials: Strategies for Assessing Workload & Tracking Time
- ☐ Achieving Diversity in Clinical Trial Accrual: The Time Has Come
- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 17. Administrator Session – Question 10

The Breakout Session (**Staffing Essentials: Strategies for Assessing Workload & Tracking Time**) provided useful and relevant information for my NCORP Role.

- ☐ No ☐ Yes
- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 18. Administrator Session – Question 11

What other topics would you like to see covered in future Administrator Sessions?

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 19. Administrator Session – Question 12

2021 NCORP Annual Meeting - Main Meeting

For the next set of questions, please select the response which best represents the extent to which you agree or disagree for the Main Meeting sessions you attended.

[Previous Question](#)[Next Question](#)

Figure 20. Main Meeting – Lead-in information

Day 1 - NCI Director's Remarks

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)[Next Question](#)

Figure 21. Main Meeting – Question 1

Day 1 - NCI Division Welcome

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)[Next Question](#)

Figure 22. Main Meeting – Question 2

Day 1 - NCORP Year in Review and Harry Hynes Award

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 23. Main Meeting – Question 3

Day 1 - Cancer Therapy Evaluation Program Update

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 24. Main Meeting – Question 4

Day 1 - Keynote Address: The Intersection Between Cancer and Vaccines

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 25. Main Meeting – Question 5

Day 1 - Meeting Update: Cancer Related Cognitive Impairment and Accrual of Older Adults to Clinical Trials

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 26. Main Meeting – Question 6

Day 1 - Assessing Site Interest and Feasibility

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 27. Main Meeting – Question 7

Day 1 - Medicaid's Role in Supporting Equitable Access to Clinical Trials

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 28. Main Meeting – Question 8

Day 1 - Ensuring Equitable Representation in Clinical Trials: NCORP Focus on Relevance and Inclusion

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 29. Main Meeting – Question 9

Day 2 - Cancer Care Delivery Research: TrACER, OaSIS, and Progress Toward 2025

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 30. Main Meeting – Question 10

Day 2 - NCORP Supported Health-Related Quality of Life Correlative Studies: Results, Impact, and Lessons Learned

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 31. Main Meeting – Question 11

Day 2 - It Takes a Village: Innovative Engagement Strategies of Key Stakeholders in Biospecimen Collection and Tissue Acquisition Trials

This session provided useful information for my NCORP role.

- ☐ Agree
- ☐ Neutral
- ☐ Disagree
- ☐ Did Not Attend

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 32. Main Meeting – Question 12

2021 NCORP Annual Meeting - Main Meeting

Did you attend a Breakout Session?

- ☐ No ☐ Yes

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 33. Main Meeting – Question 13

Please select which Breakout Session you attended.

- ☐ Communicating NCORP Research to Increase Access to the Latest in Cancer Care
- ☐ PARTNRS in Action: Collaborating with Non-oncologists Around NCORP Trials
- ☐ Incorporating Lessons from COVID into Qualitative Data Collection for CCDR Trials
- ☐ NCORP Prevention Trials: Working Together to Achieve Accrual Goals and Trial Success

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 34. Main Meeting – Question 14

The Breakout Session (**Communicating NCORP Research to Increase Access to the Latest in Cancer Care**) provided useful and relevant information for my NCORP Role.

- ☐ No ☐ Yes
- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 35. Main Meeting – Question 15

How would you rate the opportunity to interact during the Breakout Session (**Communicating NCORP Research to Increase Access to the Latest in Cancer Care**) you attended?

- ☐ Excellent
- ☐ Good
- ☐ Fair
- ☐ Poor
- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 36. Main Meeting – Question 16

How would you rate the length of the 2021 NCORP Annual Meeting?

- ☐ Too Long
- ☐ Just Right
- ☐ Too Short
- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 37. Main Meeting – Question 17

Overall, did the 2021 NCORP Annual Meeting meet your expectations?

- ☐ Exceeded Expectations
- ☐ Met Expectations
- ☐ Did not Meet Expectations

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 38. Main Meeting – Question 18

What was the most valuable part of the 2021 NCORP Virtual Annual Meeting?

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 39. Main Meeting – Question 19

What improvements or changes would you recommend for future NCORP Annual meetings?

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 40. Main Meeting – Question 20

What topics would you like to see covered in future annual meetings or webinars?

- ☐ Prefer not to Answer

Previous Question

Next Question

Figure 41. Main Meeting – Question 21

Did the virtual meeting format permit you to attend this year's NCORP Annual Meeting when you otherwise would have been unable to attend in person?

- ☐ No ☐ Yes
- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 42. Main Meeting – Question 22

What is your likelihood of attending the 2022 NCORP Annual Meeting in-person?

- ☐ Highly Likely
☐ Neutral
☐ Not Likely
- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 43. Main Meeting – Question 23

The registration website was informative.

- ☐ No ☐ Yes
- ☐ Prefer not to Answer

[Previous Question](#)

[Next Question](#)

Figure 44. Registration Website Question

How would you rate the virtual Zoom platform used?

- ☐ Excellent
☐ Good
☐ Fair
☐ Poor
- ☐ Prefer not to Answer

[Previous Question](#)

[Submit](#)

Figure 45. Zoom Platform Question

Survey Complete!

Thank you for taking the time to respond to this survey.

Figure 46. Survey Complete Screen